In this study, we investigated the effect of combinational treatment of DNMT inhibitor and PARP inhibitor on the cytotoxicity of cancer cells and found that their combination enhances cytotoxicity in both blood cancer and colon cancer cells. Here, PARP1 is linked to hematopoietic and lymphoid system neoplasm.